ArticleMalaria journal2024

Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial.

Christian Kositz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.